Skip to content

Press release -

New probiotic bacteria to improve productivity and animal welfare in the global poultry industry

Chr. Hansen is ready to launch probiotic feed additive that can prevent Necrotic enteritis in commercial poultry production.

Necrotic enteritis (NE) is a serious condition where chickens loose the ability to digest nutrients from the feed with the risk of a painful death within only few days. The condition causes much suffering for the chicken and represents a serious loss to the producers. Recent European surveys estimate the economic impact of NE on global poultry producers to $2 billion annually.

“Our new, probiotic bacteria, Bacillus, is an all natural method to prevent NE from occurring. It makes treatment with antibiotics superfluous and frees the producers of the extra management and costs of retention time before slaughtering. And last but not least, it severely raises the level of animal welfare in the production, “says Inge Knap, Director, Development and Application, Animal Health & Nutrition, Chr. Hansen.

Large market potential

The market for Bacillus is large, as the European poultry production alone amounts to 5.5 billion chickens annually (FAOSTAT). Globally, the production reaches 42 billion chickens equalling an annual production of 59 million ton chicken meat (USDAFAS, 2005)

”We see a huge potential for our new Bacillus, and look forward to going to market first in North and South America and then hopefully Europe. This new product fits perfectly in our portfolio of documented microbial products for the feed industry, which already today provides solutions for the swine, poultry and livestock industries,” says Jan Kuhlmann, Vice President, Animal Health & Nutrition, Chr. Hansen.

Probiotics are live bacteria that benefit its host. Probiotics in form of feed additives improve nutrient digestion, the intestinal microflora as well as the general health of the animals.

Topics


Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.

Contacts

Helle Rexen

Helle Rexen

Press contact Media relations officer +45 20 74 28 40

About us

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Chr. Hansen Holding A/S

Boege Allé 10-12
DK-2970 Hoersholm
Denmark